Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents
American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2025
DOI: 10.1002/ajmg.c.70008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2025. Verfasst von Alessandro De Falco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Cryptorchidism, Hand Deformities, Congenital, Intellectual Disability, Growth Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Myhre Syndrome (MYHRS, MIM #139210) is a rare, multisystem connective tissue disorder caused by recurrent heterozygous gain‐of‐function pathogenic variants in the SMAD4 gene, a key player in TGF‐β signaling and a regulator of extracellular matrix homeostasis. MYHRS is characterized by a progressive fibrotic phenotype affecting multiple organ systems, including the skeletal, cardiovascular, respiratory, and integumentary systems. MYHRS individuals often present with short stature, joint contractures, cardiac valve defects, subglottic stenosis, and skin thickening. Neurodevelopmental disorders, including autism spectrum disorder, may also occur. Despite the recurrent mutations, MYHRS individuals have significant phenotypic variability. Treatment for MYHRS is symptomatic, and no disease‐modifying therapies are currently available. In this article, we discuss potential future therapies in MYHRS, such as TGF‐β inhibitors, anti‐fibrotic drugs, and gene editing approaches. Furthermore, we discuss unmet needs on clinical and biochemical endpoints that are critical for the investigation of new therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
- Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy.
- Scuola Superiore Meridionale (SSM, School of Advanced Studies), Genomics and Experimental Medicine Program, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Alessandro De Falco, Alfonso Manuel D'Alessio, Nicola Brunetti-Pierri
Zitieren
APA
De Falco, A., D'Alessio, A. M., & Brunetti-Pierri, N. (2025). Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.70008
Vancouver
De Falco A, D'Alessio AM, Brunetti-Pierri N. Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2025. doi:10.1002/ajmg.c.70008
BibTeX
@article{DeFalco2025,
author = {De Falco, Alessandro and D'Alessio, Alfonso Manuel and Brunetti-Pierri, Nicola},
title = {Therapy for Myhre Syndrome: Goals, Misconceptions, and Current Agents},
journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
year = {2025},
doi = {10.1002/ajmg.c.70008}
}
EUVIMED